Matson Inc vs GeneDx Holdings Corp — how do they compare? Matson Inc trades at $218.37 (market cap $6.61B), while GeneDx Holdings Corp trades at $60.5 (market cap $1.80B). The key difference: Matson Inc is far larger — about 3.7× GeneDx Holdings Corp's market cap, and Matson Inc pays a 0.7% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals.
| MATX | WGS | |
|---|---|---|
Market Cap | $6.61B | $1.80B |
Sector | Technology | Technology |
52-Week High | $223.55 | $167.51 |
52-Week Low | $88.05 | $34.51 |
Enterprise Value | $7.21B | $1.80B |
Dividend Yield | 0.7% | — |
Signals from Pluang's Aura AI — not financial advice
Matson (MATX) trades at $218.41, down 1.7% today but maintains a bullish technical outlook with strong moving averages and key support at $214. The company demonstrates solid fundamentals with a P/E of 16.48, net income margin of 12.92%, and consistent earnings beats in recent quarters. Recent news highlights preliminary Q2 2026 results expecting EPS of $4.12-$4.30 and a dividend increase to $0.38 per share, reflecting management confidence.
The investment outlook remains positive given analyst consensus of 63.64% buy ratings, robust cash flow from operations, and strategic fleet modernization. Key risks include exposure to Pacific trade volatility and potential economic slowdowns impacting shipping demand. The stock's current valuation and growth trajectory present a compelling opportunity for investors seeking stable dividends and earnings growth in the shipping sector.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Trailing returns across standard periods
Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →